Achyut Healthcare Ltd. Approves Preferential Allotment of Equity Shares
Achyut Healthcare Ltd. announced on March 23, 2026, that its Board of Directors approved the allotment of 58,00,000 equity shares on a preferential basis to Promoter and Non-Promoter group shareholders. The shares are being issued at a premium of Rs.5 per equity share, with a face value of Re.1 per share.The company received a total consideration of ₹3,48,00,000 for the allotment of the 58,00,000 equity shares. The newly allotted shares will rank equally with existing shares regarding dividend payments and voting rights.
The issued, subscribed, and paid-up capital of the company following the allotment is detailed below:
| Particulars | Before Allotment | Value (Face value of ₹ 1/- each) | After Allotment | Value (Face value of ₹ 1/- each) |
|---|---|---|---|---|
| Issued Capital | 23,55,57,000 | 23,55,57,000 | 24,13,57,000 | 24,13,57,000 |
| Subscribed and Paid-up Capital | 23,55,57,000 | 23,55,57,000 | 24,13,57,000 | 24,13,57,000 |
The Board meeting commenced at 5:00 P.M. (IST) and concluded at 5:45 P.M. (IST).
Details of Allottees and Shareholding
The following table outlines the details of the allottees, their pre and post-preferential shareholding, and the number of equity shares allotted:
| Sr. No. | Allottee Name | Pre-Preferential Shareholding | Post-Issue Holding | No. of Shares Allotted |
|---|---|---|---|---|
| 1 | Akshit Mahendra Raycha | 2,07,90, 000 | 2,15,90, 000 | 8,00,000 |
| 2 | Mahendra C. Raycha HUF | 1,83,82, 770 | 1,91,82, 770 | 8,00,000 |
| 3 | Ray Remedies Private Limited | 77,17, 500 | 79,17, 500 | 2,00,000 |
| 4 | Zenith Lifecare Private Limited | - | 2,00,000 | 2,00,000 |
| 5 | Dhavalkumar Harshkantbhai | - | 10,00, 000 | 10,00,000 |
| 6 | Mayankbhai Harshkantbhai Ruparelia | - | 10,00, 000 | 10,00,000 |
| 7 | Strikar Lifescience LLP | - | 18,00, 000 | 18,00,000 |
| TOTAL | 58,00,000 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.